Ardelyx
Edit

Ardelyx

http://www.ardelyx.com/
Last activity: 12.03.2024
Categories: TechnologyTalentResearchProductMedTechMarketManagementDrugDevelopmentBioTech
Our research expertise on biological mechanisms and pathways has enabled us to develop a pipeline of drug candidates designed to address important unmet clinical needs, including better management of complications related to kidney and cardiovascular diseases, with the goal of improving outcomes for this large population of underserved patients. Our lead candidate tenapanor, is a first-in-class, targeted, small molecule for the control of serum phosphorus in adult patients with chronic kidney disease on dialysis. We are also developing earlier-stage candidates that further leverage our discovery capabilities and deep understanding of transport mechanisms, targeting specific pharmacologic pathways. Ardelyx is publicly traded on the Nasdaq Global Market under the symbol ARDX. Tapping into the best talent on both coasts and everywhere in between, we maintain dual headquarters in the greater San Francisco and Boston biotech communities.
Likes
92
Followers
1.09K
Website visits
5.9K /mo.
Mentions
20
Location: United States, California, Fremont
Employees: 51-200
Phone: +1 510-745-1700
Total raised: $82.5M
Founded date: 2007
Twitter
Facebook
LinkedIn
Email

Investors 2

Funding Rounds 3

DateSeriesAmountInvestors
24.02.2022-$27.5M-
15.05.2014-$25M-
31.08.2011Series B$30M-

Mentions in press and media 20

DateTitleDescriptionSource
12.03.2024Ardelyx, Inc. Reports Employment Inducement GrantsWALTHAM, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical...einpresswi...
22.02.2024Ardelyx Reports Fourth Quarter and Full Year 2023 Financial ...Strong commercial performance of IBSRELA continues, ending FY 2023 with $80.1 million in net product...einpresswi...
02.03.2023Ardelyx Reports Fourth Quarter and Full Year 2022 Financial .../EIN News/ -- Continued successful launch of IBSRELA, ending FY 2022 with $15.6 million in net produ...einpresswi...
03.09.2021Ardelyx Announces Publication of 52-Week Phase 3 PHREEDOM Tr...prnewswire...
29.07.2021Ardelyx : Receives Complete Response Letter from U.S. FDA fo...FREMONT, Calif. and WALTHAM, Mass., July 29, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a bi...marketscre...
29.07.2021Ardelyx Receives Complete Response Letter from U.S. FDA for ...prnewswire...
07.06.2021Ardelyx Announces Presentations at ERA-EDTA Virtual Congress...prnewswire...
29.04.2021Ardelyx Announces Extension of the PDUFA Review Period for T...prnewswire...
14.04.2021Ardelyx Collaboration Partner, Kyowa Kirin, Announces Initia...prnewswire...
12.04.2021Ardelyx Announces Upcoming Data Presentation at ISN World Co...prnewswire...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In